Table 4 Risk of prostate cancer death by statin use after ADT stratified by various baseline variables.
Participants/deaths | Risk of PCA death among ADT treated patients with statin use | |||
|---|---|---|---|---|
Age-adjusted | Multivariable adjusted | |||
HR (95% CI) | HR (95% CI)* | |||
FinRSPC randomization group | Control arm | 2815/547 | 0.70 (0.58–0.84) | 0.80 (0.66–0.98) |
Screening arm | 1613/287 | 0.64 (0.49–0.84) | 0.63 (0.48–0.83) | |
Statin use before ADT | No | 2904/593 | 0.58 (0.46–0.73) | 0.67 (0.53–0.84) |
Yes | 1524/241 | 0.68 (0.51–0.91) | 0.88 (0.66–1.18) | |
Metastatic PCa at diagnosis | No | 3871/501 | 0.75 (0.62–0.90) | 0.74 (0.61–0.90) |
Yes | 556/333 | 0.88 (0.66–1.17) | 0.93 (0.69–1.24) | |
PCa risk group** | Low risk | 768/72 | 0.68 (0.41–1.11) | 0.71 (0.43–1.20) |
Intermediate risk | 1639/150 | 0.72 (0.51–1.01) | 0.62 (0.44–0.88) | |
High risk | 2021/612 | 0.77 (0.64–0.92) | 0.78 (0.64–0.94) | |
Choice of primary treatment | Active surveillance | 390/31 | 0.76 (0.35–1.63) | 0.76 (0.34–1.70) |
Radical prostatectomy | 332/60 | 0.75 (0.42–1.31) | 0.85 (0.48–1.53) | |
Radical radiotherapy | 538/90 | 0.74 (0.48–1.16) | 0.74 (0.46–1.18) | |
Radiation therapy | No | 2172/582 | 0.70 (0.58–0.86) | 0.85 (0.69–1.04) |
Before ADT | 299/62 | 0.70 (0.41–1.20) | 0.67 (0.38–1.16) | |
After ADT | 1957/190 | 0.82 (0.61–1.11) | 0.77 (0.57–1.06) | |
Use of antidiabetic drugs | No | 3463/661 | 0.68 (0.57–0.82) | 0.74 (0.62–0.90) |
Yes | 965/173 | 0.68 (0.50–0.94) | 0.74 (0.53–1.02) | |
Socioeconomic status | Employed | 503/119 | 0.79 (0.53–1.18) | 0.88 (0.58–1.34) |
Unemployed | 111/23 | 0.53 (0.15–1.83) | 0.77 (0.21–2.86) | |
Retired | 3772/677 | 0.66 (0.56–0.79) | 0.71 (0.60–0.85) | |
Marital status | Single/divorced/widow | 1244/263 | 0.67 (0.50–0.89) | 0.74 (0.55–1.01) |
Married/registered partnership | 3184/571 | 0.70 (0.59–0.84) | 0.75 (0.62–0.91) | |
